558 related articles for article (PubMed ID: 22282184)
21. Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium.
Gupta RT; Iseman CM; Leyendecker JR; Shyknevsky I; Merkle EM; Taouli B
AJR Am J Roentgenol; 2012 Jul; 199(1):35-43. PubMed ID: 22733891
[TBL] [Abstract][Full Text] [Related]
22. Histopathologically confirmed focal nodular hyperplasia of the liver: gadoxetic acid-enhanced MRI characteristics.
Grieser C; Steffen IG; Seehofer D; Kramme IB; Uktolseya R; Scheurig-Muenkler C; Hamm B; Denecke T
Magn Reson Imaging; 2013 Jun; 31(5):755-60. PubMed ID: 23219272
[TBL] [Abstract][Full Text] [Related]
23. Contrast-enhanced ultrasound in combination with color Doppler ultrasound can improve the diagnostic performance of focal nodular hyperplasia and hepatocellular adenoma.
Kong WT; Wang WP; Huang BJ; Ding H; Mao F; Si Q
Ultrasound Med Biol; 2015 Apr; 41(4):944-51. PubMed ID: 25701530
[TBL] [Abstract][Full Text] [Related]
24. Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging.
Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
Radiology; 2014 Jun; 271(3):748-60. PubMed ID: 24588677
[TBL] [Abstract][Full Text] [Related]
25. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI.
Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T
AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786
[TBL] [Abstract][Full Text] [Related]
26. HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI.
Auer TA; Walter-Rittel T; Geisel D; Schöning W; Schmelzle M; Müller T; Sinn B; Denecke T; Hamm B; Fehrenbach U
BMC Med Imaging; 2021 Feb; 21(1):28. PubMed ID: 33588783
[TBL] [Abstract][Full Text] [Related]
27. Morphologic and Molecular Features of Hepatocellular Adenoma with Gadoxetic Acid-enhanced MR Imaging.
Ba-Ssalamah A; Antunes C; Feier D; Bastati N; Hodge JC; Stift J; Cipriano MA; Wrba F; Trauner M; Herold CJ; Caseiro-Alves F
Radiology; 2015 Oct; 277(1):104-13. PubMed ID: 25985059
[TBL] [Abstract][Full Text] [Related]
28. Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful?
Roux M; Pigneur F; Baranes L; Calderaro J; Chiaradia M; Decaens T; Kastahian S; Charles-Nelson A; Tselikas L; Costentin C; Laurent A; Azoulay D; Mallat A; Rahmouni A; Luciani A
Abdom Radiol (NY); 2018 Jul; 43(7):1670-1681. PubMed ID: 29110059
[TBL] [Abstract][Full Text] [Related]
29. Hepatic Adenoma Subtypes on Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI: Systematic Review and Meta-Analysis.
Kim TH; Woo S; Ebrahimzadeh S; McInnes MDF; Gerst SR; Do RK
AJR Am J Roentgenol; 2023 Jan; 220(1):28-38. PubMed ID: 35920706
[No Abstract] [Full Text] [Related]
30. Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images.
Kang Y; Lee JM; Kim SH; Han JK; Choi BI
Radiology; 2012 Sep; 264(3):751-60. PubMed ID: 22798225
[TBL] [Abstract][Full Text] [Related]
31. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy.
Sciarra A; Schmidt S; Pellegrinelli A; Maggioni M; Dondossola D; Pasquier J; Cigala C; Tosi D; Halkic N; Bulfamante G; Viale G; Bosari S; Balabaud C; Bioulac-Sage P; Sempoux C
Liver Int; 2019 Jan; 39(1):158-167. PubMed ID: 30218633
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of morphological enhancement patterns in the hepatobiliary phase of gadoxetic acid-enhanced MRI to distinguish focal nodular hyperplasia from hepatocellular adenoma.
Bilreiro C; Soler JC; Ayuso JR; Caseiro-Alves F; Ayuso C
Radiol Med; 2021 Nov; 126(11):1379-1387. PubMed ID: 34287759
[TBL] [Abstract][Full Text] [Related]
33. Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.
Reizine E; Amaddeo G; Pigneur F; Baranes L; Legou F; Mulé S; Zegai B; Roche V; Laurent A; Rahmouni A; Calderaro J; Luciani A
Eur Radiol; 2018 Oct; 28(10):4243-4253. PubMed ID: 29721686
[TBL] [Abstract][Full Text] [Related]
34. Washout appearance in Gd-EOB-DTPA-enhanced MR imaging: A differentiating feature between hepatocellular carcinoma with paradoxical uptake on the hepatobiliary phase and focal nodular hyperplasia-like nodules.
Kim JW; Lee CH; Kim SB; Park BN; Park YS; Lee J; Park CM
J Magn Reson Imaging; 2017 Jun; 45(6):1599-1608. PubMed ID: 27726242
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT--initial observations.
Huppertz A; Haraida S; Kraus A; Zech CJ; Scheidler J; Breuer J; Helmberger TK; Reiser MF
Radiology; 2005 Feb; 234(2):468-78. PubMed ID: 15591431
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic Value of Gadoxetic Acid-Enhanced MR Imaging to Distinguish HCA and Its Subtype from FNH: A Systematic Review.
Guo Y; Li W; Cai W; Zhang Y; Fang Y; Hong G
Int J Med Sci; 2017; 14(7):668-674. PubMed ID: 28824299
[No Abstract] [Full Text] [Related]
37. [Focal nodular hyperplasia and hepatocellular adenoma].
Bastati-Huber N; Pötter-Lang S; Ba-Ssalamah A
Radiologe; 2015 Jan; 55(1):18-26. PubMed ID: 25575723
[TBL] [Abstract][Full Text] [Related]
38. Imaging modalities for focal nodular hyperplasia and hepatocellular adenoma.
van den Esschert JW; van Gulik TM; Phoa SS
Dig Surg; 2010; 27(1):46-55. PubMed ID: 20357451
[TBL] [Abstract][Full Text] [Related]
39. Characterization of hepatocellular tumors: value of mangafodipir-enhanced magnetic resonance imaging.
Scharitzer M; Schima W; Schober E; Reimer P; Helmberger TK; Holzknecht N; Stadler A; Ba-Ssalamah A; Weber M; Wrba F
J Comput Assist Tomogr; 2005; 29(2):181-90. PubMed ID: 15772534
[TBL] [Abstract][Full Text] [Related]
40. Utility of volumetric contrast-enhanced and diffusion-weighted MRI in differentiating between common primary hypervascular liver tumors.
Zarghampour M; Fouladi DF; Pandey A; Ghasabeh MA; Pandey P; Varzaneh FN; Khoshpouri P; Shao N; Pan L; Grimm R; Kamel IR
J Magn Reson Imaging; 2018 Oct; 48(4):1080-1090. PubMed ID: 29630756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
